Sign In
Buy RPTX
$2.65
+0 (+0%)
At Close: Apr 24, 2026
Repare Therapeutics Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - RPTX
12:15pm, Tuesday, 05'th Mar 2024
NEW YORK, NY / ACCESSWIRE / March 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Repare Therapeutics Inc. ("Repare Therapeutics") (NASDAQ:RPTX) concerning poss
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX
10:15am, Sunday, 03'rd Mar 2024
NEW YORK , March 3, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ: RPTX). Such investors are a
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
07:05am, Thursday, 29'th Feb 2024
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that mem
ATTENTION Repare Therapeutics Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights
04:15pm, Wednesday, 28'th Feb 2024
NEW YORK, NY / ACCESSWIRE / February 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Repare Therapeutics Inc. ("Repare Therapeutics") (NASDAQ:RPTX) concerning
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
07:05am, Wednesday, 28'th Feb 2024
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial
Repare Therapeutics Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - RPTX
01:30pm, Tuesday, 27'th Feb 2024
NEW YORK, NY / ACCESSWIRE / February 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Repare Therapeutics Inc. ("Repare Therapeutics") (NASDAQ:RPTX) concerning
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX
10:00am, Saturday, 24'th Feb 2024
NEW YORK , Feb. 24, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ: RPTX). Such investors are ad
Repare Therapeutics Inc. (RPTX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
11:06am, Tuesday, 20'th Feb 2024
Repare Therapeutics Inc. (RPTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Repare Therapeutics Inc. (RPTX)
06:28pm, Friday, 16'th Feb 2024
NEW YORK--(BUSINESS WIRE)---- $RPTX #ClassActionLawsuit--The law firm of Kirby McInerney LLP is investigating potential claims against Repare Therapeutics Inc. (“Repare” or the “Company”) (NAS
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX
06:10pm, Thursday, 15'th Feb 2024
NEW YORK , Feb. 15, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ: RPTX). Such investors are adv
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664
07:05am, Thursday, 15'th Feb 2024
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the firs
Repare Therapeutics Inc. (RPTX) Soars 8.8%: Is Further Upside Left in the Stock?
05:46am, Tuesday, 13'th Feb 2024
Repare Therapeutics Inc. (RPTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further pri
Repare Therapeutics to Regain Global Rights to Camonsertib
04:05pm, Monday, 12'th Feb 2024
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, announced today that it
Repare Therapeutics (RPTX) Rises 34% in a Week: Here's Why
09:46am, Monday, 20'th Nov 2023
Repare Therapeutics (RPTX) rises 34% in a week after announcing plans to begin clinal-stage development of two additional candidates, RP-1664 and RP-3467, in 2024 in several solid tumor indications.
Repare: Potential Of Camonsertib With Several Shots On Goal
07:43pm, Monday, 06'th Nov 2023
Repare Therapeutics presented preliminary results from the phase 1 MYTHIC study using the lunresertib and camonsertib combination for the treatment of patients with multiple solid tumor types. The bio
